LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 32

Search options

  1. Article ; Online: The importance of being generic: Avoiding brand names for safety and clarity.

    Hambrick, H Rhodes / Tang Girdwood, Sonya

    Journal of hospital medicine

    2023  Volume 18, Issue 9, Page(s) 870–871

    MeSH term(s) Humans ; Drug Prescriptions ; Drugs, Generic
    Chemical Substances Drugs, Generic
    Language English
    Publishing date 2023-07-31
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 2233783-0
    ISSN 1553-5606 ; 1553-5592
    ISSN (online) 1553-5606
    ISSN 1553-5592
    DOI 10.1002/jhm.13177
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Professionalism or prejudice? Modelling roles, risking microaggressions.

    Miller, Emily / Tang Girdwood, Sonya / Shah, Anita / Anyigbo, Chidiogo / Lanphier, Elizabeth

    Journal of medical ethics

    2023  Volume 49, Issue 12, Page(s) 822–823

    MeSH term(s) Humans ; Professionalism ; Microaggression ; Prejudice ; Ethics, Medical
    Language English
    Publishing date 2023-11-23
    Publishing country England
    Document type Journal Article
    ZDB-ID 194927-5
    ISSN 1473-4257 ; 0306-6800
    ISSN (online) 1473-4257
    ISSN 0306-6800
    DOI 10.1136/jme-2023-109295
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Current Practices in Pharmacogenomics.

    Ramsey, Laura B / Prows, Cynthia A / Tang Girdwood, Sonya / Van Driest, Sara

    Pediatric clinics of North America

    2023  Volume 70, Issue 5, Page(s) 995–1011

    Abstract: Pharmacogenomics, where genomic information is used to tailor medication management, is a strategy to maximize drug efficacy and minimize toxicity. Although pediatric evidence is less robust than for adults, medications influenced by pharmacogenomics are ...

    Abstract Pharmacogenomics, where genomic information is used to tailor medication management, is a strategy to maximize drug efficacy and minimize toxicity. Although pediatric evidence is less robust than for adults, medications influenced by pharmacogenomics are prescribed to children and adolescents. Evidence-based guidelines and drug label annotations are available from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Pharmacogenomics Knowledgebase (PharmGKB). Some pediatric health care facilities use pharmacogenomics to provide dosing recommendations to pediatricians. Herein, we use a case-based approach to illustrate the use of pharmacogenomic data in pediatric clinical care and provide resources for finding and using pharmacogenomic guidelines.
    MeSH term(s) Adolescent ; Adult ; Humans ; Child ; Pharmacogenetics ; Pediatricians
    Language English
    Publishing date 2023-07-03
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, N.I.H., Extramural
    ZDB-ID 215711-1
    ISSN 1557-8240 ; 0031-3955
    ISSN (online) 1557-8240
    ISSN 0031-3955
    DOI 10.1016/j.pcl.2023.05.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Major Drug-Drug Interaction Exposure Among Medicaid-Insured Children in the Outpatient Setting.

    Kyler, Kathryn E / Hall, Matt / Antoon, James W / Goldman, Jennifer / Shah, Samir S / Tang Girdwood, Sonya / Williams, Derek J / Feinstein, James A

    Pediatrics

    2024  Volume 153, Issue 2

    MeSH term(s) Child ; Humans ; Outpatients ; Cross-Sectional Studies ; Medicaid ; Drug Interactions ; Drug-Related Side Effects and Adverse Reactions
    Language English
    Publishing date 2024-01-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 207677-9
    ISSN 1098-4275 ; 0031-4005
    ISSN (online) 1098-4275
    ISSN 0031-4005
    DOI 10.1542/peds.2023-063506
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Partnering with Clinical Pharmacologists to Improve Medication Use in Children.

    Miyagi, Shogo John / Lam, Edwin / Tang Girdwood, Sonya

    The Journal of pediatrics

    2020  Volume 227, Page(s) 5–8

    MeSH term(s) Child ; Child, Preschool ; Drug Labeling/legislation & jurisprudence ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Humans ; Infant ; Infant, Newborn ; Off-Label Use ; Pediatrics/organization & administration ; Pharmaceutical Preparations/administration & dosage ; Pharmacology, Clinical/education ; Pharmacology, Clinical/organization & administration
    Chemical Substances Pharmaceutical Preparations
    Language English
    Publishing date 2020-12-15
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural
    ZDB-ID 3102-1
    ISSN 1097-6833 ; 0022-3476
    ISSN (online) 1097-6833
    ISSN 0022-3476
    DOI 10.1016/j.jpeds.2020.03.061
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Cefepime-Associated Neurotoxicity in a Pediatric Patient With Stage V Chronic Kidney Disease.

    Hambrick, Horace Rhodes / Pavia, Kathryn / Tang Girdwood, Sonya / Lazear, Danielle / Taylor, John Michael / Benoit, Stefanie

    Journal of pharmacy practice

    2022  Volume 37, Issue 1, Page(s) 243–247

    Abstract: Background: ...

    Abstract Background:
    MeSH term(s) Child, Preschool ; Humans ; Anti-Bacterial Agents ; Cefepime/adverse effects ; Neurotoxicity Syndromes/diagnosis ; Neurotoxicity Syndromes/etiology ; Renal Insufficiency/drug therapy ; Renal Insufficiency, Chronic/chemically induced ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/drug therapy ; Seizures
    Chemical Substances Anti-Bacterial Agents ; Cefepime (807PW4VQE3)
    Language English
    Publishing date 2022-09-08
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 1027474-1
    ISSN 1531-1937 ; 0897-1900
    ISSN (online) 1531-1937
    ISSN 0897-1900
    DOI 10.1177/08971900221125000
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Ceftriaxone Pharmacokinetics and Pharmacodynamics in 2 Pediatric Patients on Extracorporeal Membrane Oxygenation Therapy.

    Cervantes, Francisco C / Mizuno, Tomoyuki / Dong, Min / Tang, Peter / Arbough, Trent / Vinks, Alexander A / Kaplan, Jennifer M / Tang Girdwood, Sonya C

    Therapeutic drug monitoring

    2023  Volume 45, Issue 6, Page(s) 832–836

    Abstract: Background: Critically ill patients with cardiac or respiratory failure may require extracorporeal membrane oxygenation (ECMO). Antibiotics are frequently administered when the suspected cause of organ failure is an infection. Ceftriaxone, a β-lactam ... ...

    Abstract Background: Critically ill patients with cardiac or respiratory failure may require extracorporeal membrane oxygenation (ECMO). Antibiotics are frequently administered when the suspected cause of organ failure is an infection. Ceftriaxone, a β-lactam antibiotic, is commonly used in patients who are critically ill. Although studies in adults on ECMO have suggested minimal impact on ceftriaxone pharmacokinetics, limited research exists on ceftriaxone pharmacokinetics/pharmacodynamics (PK/PD) in pediatric ECMO patients. We report the PK profiles and target attainment of 2 pediatric patients on ECMO who received ceftriaxone.
    Methods: Ceftriaxone concentrations were measured in 2 pediatric patients on ECMO using scavenged opportunistic sampling. PK profiles were generated and individual PK parameters were estimated using measured free ceftriaxone concentrations and a published population PK model in children who are critically ill, using Bayesian estimation.
    Results: Patient 1, an 11-year-old boy on venovenous ECMO for respiratory failure received 2 doses of 52 mg/kg ceftriaxone 12 hours apart while on ECMO and additional doses every 12 hours off ECMO. On ECMO, ceftriaxone clearance was 13.0 L/h/70 kg compared with 7.6 L/h/70 kg off ECMO, whereas the model-predicted mean clearance in children who are critically ill without ECMO support was 6.54 L/h/70 kg. Patient 2, a 2-year-old boy on venoarterial ECMO due to cardiac arrest received 50 mg/kg ceftriaxone every 12 hours while on ECMO for >7 days. Only clearance while on ECMO could be estimated (9.1 L/h/70 kg). Trough concentrations in both patients were >1 mg/L (the breakpoint for Streptococcus pneumoniae ) while on ECMO.
    Conclusions: ECMO increased ceftriaxone clearance above the model-predicted clearances in the 2 pediatric patients studied. Twelve-hour dosing allowed concentrations to remain above the breakpoint for commonly targeted bacteria but not 4 times the breakpoint in one patient, suggesting that precision dosing may be beneficial to ensure target attainment in children on ECMO.
    MeSH term(s) Adult ; Male ; Humans ; Child ; Child, Preschool ; Extracorporeal Membrane Oxygenation ; Ceftriaxone/therapeutic use ; Critical Illness/therapy ; Bayes Theorem ; Anti-Bacterial Agents/pharmacokinetics ; Respiratory Insufficiency/drug therapy
    Chemical Substances Ceftriaxone (75J73V1629) ; Anti-Bacterial Agents
    Language English
    Publishing date 2023-09-12
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 424443-6
    ISSN 1536-3694 ; 0163-4356
    ISSN (online) 1536-3694
    ISSN 0163-4356
    DOI 10.1097/FTD.0000000000001133
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Piperacillin pharmacokinetics and pharmacodynamics in paediatric patients who received high frequency intra-operative piperacillin/tazobactam dosing.

    McIntire, Carter / Luna Torres, Julie / Tang, Peter / Vinks, Alexander A / Kaplan, Jennifer / Tang Girdwood, Sonya

    International journal of antimicrobial agents

    2023  Volume 63, Issue 3, Page(s) 107079

    Abstract: Piperacillin/tazobactam (PTZ) is a broad-spectrum antibiotic, typically dosed every six hours (q6h). Guidelines recommend dosing PTZ every 2 hours (q2h) intra-operatively for complex abdominal surgery, including liver transplant. The data supporting the ... ...

    Abstract Piperacillin/tazobactam (PTZ) is a broad-spectrum antibiotic, typically dosed every six hours (q6h). Guidelines recommend dosing PTZ every 2 hours (q2h) intra-operatively for complex abdominal surgery, including liver transplant. The data supporting the guidelines for intra-operative dosing are sparse and the pharmacokinetics/pharmacodynamics (PK/PD) of q2h dosing has not been studied by simulation or in humans. In this study, PK/PD parameters of high-frequency intra-operative dosing and q6h post-operative dosing were compared in critically ill children. Paediatric patients who received PTZ during complex abdominal surgery or transplant and who had intra-operative and post-operative opportunistic samples were included. Using a published PK model and observed concentrations, individual piperacillin PK/PD parameters were estimated using Bayesian estimation. Alternative post-operative dosing strategies were simulated using the patients with the highest and lowest estimated piperacillin clearance. Thirteen patients were included (median age: 3.1 years, 85% liver transplant recipients). PK parameters in the intra-operative and post-operative phases were not significantly different (clearance: 15.8 ± 7.2 vs. 12.6 ± 6.3 L/h/70 kg, P=0.070; central volume: 13.4 [13.1, 13.8] vs. 15.2 [12.2, 16.0] L/70 kg, P=0.22). At an individual level, intra-operative clearance values were -35% to 139% of the post-operative values, whereas central volume intra-operative values were -40% to 77% of the post-operative values. Intra-operative piperacillin exposure was higher during high-frequency dosing compared with the post-operative period (AUC/h: 109 [93.4, 127] vs. 62.8 [41.6, 78.3] mg/L, P=0.002). Simulations showed great variation in optimal dosing strategies that would minimise toxicity and maximise efficacy, indicating a role for individualised dosing in paediatric surgical populations.
    MeSH term(s) Humans ; Child ; Child, Preschool ; Piperacillin/therapeutic use ; Bayes Theorem ; Piperacillin, Tazobactam Drug Combination ; Anti-Bacterial Agents ; Computer Simulation
    Chemical Substances Piperacillin (X00B0D5O0E) ; Piperacillin, Tazobactam Drug Combination (157044-21-8) ; Anti-Bacterial Agents
    Language English
    Publishing date 2023-12-30
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2023.107079
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Opportunities for Pharmacogenetic Testing to Guide Dosing of Medications in Youths With Medicaid.

    Tang Girdwood, Sonya / Hall, Matthew / Antoon, James W / Kyler, Kathryn E / Williams, Derek J / Shah, Samir S / Orth, Lucas E / Goldman, Jennifer / Feinstein, James A / Ramsey, Laura B

    JAMA network open

    2024  Volume 7, Issue 2, Page(s) e2355707

    Abstract: Importance: There are an increasing number of medications with a high level of evidence for pharmacogenetic-guided dosing (PGx drugs). Knowledge of the prevalence of dispensings of PGx drugs and their associated genes may allow hospitals and clinical ... ...

    Abstract Importance: There are an increasing number of medications with a high level of evidence for pharmacogenetic-guided dosing (PGx drugs). Knowledge of the prevalence of dispensings of PGx drugs and their associated genes may allow hospitals and clinical laboratories to determine which pharmacogenetic tests to implement.
    Objectives: To investigate the prevalence of outpatient dispensings of PGx drugs among Medicaid-insured youths, determine genes most frequently associated with PGx drug dispenses, and describe characteristics of youths who were dispensed at least 1 PGx drug.
    Design, setting, and participants: This serial cross-sectional study includes data from 2011 to 2019 among youths aged 0 to 17 years in the Marketscan Medicaid database. Data were analyzed from August to December 2022.
    Main outcomes and measures: PGx drugs were defined as any medication with level A evidence as determined by the Clinical Pharmacogenetics Implementation Consortium (CPIC). The number of unique youths dispensed each PGx drug in each year was determined. PGx drugs were grouped by their associated genes for which there was CPIC level A evidence to guide dosing, and a dispensing rate (No. of PGx drugs/100 000 youths) was determined for each group for the year 2019. Demographics were compared between youths dispensed at least 1 PGx drug and those not dispensed any PGx drugs.
    Results: The number of Medicaid-insured youths queried ranged by year from 2 078 683 youths in 2011 to 4 641 494 youths in 2017, including 4 126 349 youths (median [IQR] age, 9 [5-13] years; 2 129 926 males [51.6%]) in 2019. The proportion of Medicaid-insured youths dispensed PGx drugs increased from 289 709 youths (13.9%; 95% CI, 13.8%-14.0%) in 2011 to 740 072 youths (17.9%; 95% CI, 17.9%-18.0%) in 2019. Genes associated with the most frequently dispensed medications were CYP2C9, CYP2D6, and CYP2C19 (9197.0 drugs [95% CI, 9167.7-9226.3 drugs], 8731.5 drugs [95% CI, 8702.5-8759.5 drugs], and 3426.8 drugs [95% CI, 3408.1-3443.9 drugs] per 100 000 youths, respectively). There was a higher percentage of youths with at least 1 chronic medical condition among youths dispensed at least 1 PGx drug (510 445 youths [69.0%; 95% CI, 68.8%-69.1%]) than among 3 386 277 youths dispensed no PGx drug (1 381 544 youths [40.8%; 95% CI, 40.7%-40.9%) (P < .001) in 2019.
    Conclusions and relevance: In this study, there was an increasing prevalence of dispensings for PGx drugs. This finding suggests that pharmacogenetic testing of specific drug-gene pairs should be considered for frequently prescribed PGx drugs and their implicated genes.
    MeSH term(s) Male ; United States ; Humans ; Adolescent ; Child, Preschool ; Child ; Pharmacogenomic Testing ; Cross-Sectional Studies ; Medicaid ; Cytochrome P-450 CYP2D6 ; Databases, Factual
    Chemical Substances Cytochrome P-450 CYP2D6 (EC 1.14.14.1)
    Language English
    Publishing date 2024-02-05
    Publishing country United States
    Document type Journal Article
    ISSN 2574-3805
    ISSN (online) 2574-3805
    DOI 10.1001/jamanetworkopen.2023.55707
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: From Dose to Exposure: Shifting the Paradigm of Pediatric Clinical Pharmacology Research and Education.

    Morales Junior, Ronaldo / Amajor, Victor / Paice, Kelli / Kyler, Kathryn E / Hambrick, H Rhodes / Pavia, Kathryn E / Haynes, Andrew S / Gooden, Felicia / Pais, Gwendolyn M / Downes, Kevin J / Ramsey, Laura B / Wagner, Jonathan / Tang Girdwood, Sonya

    Clinical pharmacology and therapeutics

    2024  

    Language English
    Publishing date 2024-04-30
    Publishing country United States
    Document type Journal Article
    ZDB-ID 123793-7
    ISSN 1532-6535 ; 0009-9236
    ISSN (online) 1532-6535
    ISSN 0009-9236
    DOI 10.1002/cpt.3281
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top